Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.

ABSTRACT:

Background

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by two major and interconnected hallmarks: inflammation and progressive neurodegeneration.

Objective

The aim of this work was to compare neurodegenerative processes, in the form of global and regional brain volume loss rates, in healthy controls (HCs) and in patients with relapsing MS (RMS) treated with ocrelizumab, which suppresses acute inflammation.

Methods

Whole brain, white matter, cortical gray matter, thalamic, and cerebellar volume loss rates were assessed in 44 HCs that were part of a substudy in the OPERA II randomized controlled trial (NCT01412333) and 59 patients with RMS enrolled in the same substudy as well as age- and sex-matched patients in OP

SUBMITTER: Kolind S 

PROVIDER: S-EPMC10176619 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature